🙌🏻Read HCmed’s latest publication in Pulmonary and Nasal Drug Delivery, Issue No 167, of ONdrugDelivery

The HCmed's team describes the value that customisable nebuliser platforms bring to patient adherence

The overall scope of the study presents the benefits of an exploratory work at the development stage of a new drug-nebuliser combination product, aiming to identify the most suitable pair for the targeted delivery requirements.

The HCmed's team looks at the advantages of customisable nebuliser platforms for new combination products

The investigations revealed the potential efficacy of IFN-β in the treatment of IPF with the mesh nebulizer, demonstrating the higher efficiency of IFN-β delivered through the mesh nebulizer.

HCmed Innovations considers patient adherence and the role the company's mesh nebuliser places in monitoring it

The breath-actuated function of the mesh nebuliser, AdheResp, allowed for a substantial reduction in fugitive aerosol emission, demonstrating the benefits of breath actuation to reduce risk to fugitive aerosol exposure during nebulisation treatment.

HCmed Innovations summarizes the development process of drug-nebulizer combination products, describing a roadmap from early development to commercialization.

This study aimed to evaluate two in-vitro test methods when assessing delivered dose for a breath-actuated mesh nebulizer, which only relies on a breathing simulator and the new method that incorporates a mixing inlet.